Carmustine (BiCNU, Gliadel)
Other Medications · Approved since 1977
Description
Carmustine is an alkylating chemotherapy agent from the nitrosourea class that has been evaluated in combination regimens for metastatic colorectal cancer. This lipophilic agent crosses the blood-brain barrier and acts as a DNA cross-linking agent, causing cell cycle arrest and apoptosis in rapidly dividing cancer cells. In colorectal cancer, carmustine has been incorporated into multi-drug combination protocols, though it is not considered a standard first-line therapy for this indication.
Mechanism of Action
Carmustine functions as a bifunctional alkylating agent that forms covalent bonds with DNA, creating interstrand and intrastrand cross-links that prevent DNA replication and transcription. The drug also carbamoylates proteins, particularly enzymes involved in DNA repair, which enhances its cytotoxic effects and prevents cellular recovery from DNA damage.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | BiCNU, Gliadel |
| Category | Other Medications |
 Status | Off-label |
 EMA Status | EMA Approved |
 Spain Access | Hospital use off-label in CRC |
| Administration | IV |
| Year Approved | 1977 |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.